New York, NY (Vocus/PRWEB) March 30, 2011
Dr. Lindsay Rosenwald enjoys unparalleled success as a venture capitalist and entrepreneur in the biotechnology industry. As arguably the most prolific entrepreneur within the industry today, Dr. Rosenwald has a diverse portfolio of successful companies which has only enhanced his success and expertise in the industry. Primarily focused on the biotechnology and pharmaceutical industry, Dr. Rosenwald has also enjoyed success with his investing experiences. Perhaps the most well known accomplishment of his is Arsenic Trioxide, a new drug which is used to treat a discriminating form leukemia. Within a 30 month time frame Dr. Rosenwald was able to bring Arsenic Trioxide from development to approval through the FDA, which is virtually unheard of.
Dr.Lindsay Rosenwald’s proclivity for biotech companies and medical advancements has helped him to found many companies which have brought several notable contributions to the medical and pharmaceutical industry. With the founding of such companies as Cypress Biosciences, PolaRX Biopharmaceuticals, Keryx Biopharmaceuticals and Chelsea Therapeutics, the development of viable treatments for cancer, leukemia, schizophrenia, fibromyalgia, rheumatoid arthritis and H1N1 has occurred.
Dr. Rosenwald’s portfolio consists of a number of firsts which has made him the field’s vanguard. Included in this list of achievements is the development of the first anti-obesity drug within the American market, as well as founding the first publicly traded cancer vaccine company, first publicly traded gene therapy company, and the first publicly traded stem cell company. The last two are quite the accomplishment considering lobbying opponents to such biotechnology.
Dr. Lindsay Rosenwald graduated Penn State University with a Bachelors of Science in Finance and received induction into the School of Business Honor Society, Beta Gamma Sigma. Despite a degree in business Dr. Rosenwald was still drawn to medicine and decided to enroll in Temple University of Medicine, interned at Abington Hospital Medical School in Philadelphia and in 1983 received his Doctors of Medicine. In 1986Lindsay Rosenwald decided to pursue his passion for finance and secured a position as physician/analyst, a very exclusive position with very few available on Wall Street.
Dr. Lindsay Rosenwald holds that within the next 20 years the demand for safe and effective treatments will only increase and it will be the smaller companies who are able to focus their research on only several projects that will be making the critical breakthroughs. It is with that in mind, as well as his commitment to the medical establishment, that Dr. Rosenwald also created the Rosenwald Foundation, a charitable organization with a focus on supporting the medical community.